Publications by authors named "Aparna Deora"

Claim this Profile
B
Biopharmaceutical Industry Practices for Sequence Variant Analyses of Recombinant Protein Therapeutics.
John Valliere-Douglass, Lisa Marzilli, Aparna Deora, Zhimei Du, Luhong He

PDA J Pharm Sci Technol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of preexisting anti-carrier immunity on subsequent responses to CRM197 or Qb-VLP conjugate vaccines.
Michael J McCluskie, Dana M Evans, Ningli Zhang, Michelle Benoit, Susan P McElhiney, Aparna Deora

Immunopharmacol Immunotoxicol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-IgE Qb-VLP Conjugate Vaccine Self-Adjuvants through Activation of TLR7.
Bassel Akache, Risini D Weeratna, Aparna Deora, Jennifer M Thorn, Brian Champion

Vaccines (Basel)· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of toll-like receptor assays to detect and identify microbial contaminants in biological products.
Li-Yun Huang, James L Dumontelle, Melissa Zolodz, Aparna Deora, Ned M Mozier

J Clin Microbiol· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.
Louise R Howe, Kotha Subbaramaiah, Jay Patel, Jaime L Masferrer, Aparna Deora

Cancer Res· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis